COMPANY
Biogen
FDA-approved therapeutic company FDA-cleared device company Clinical Phase 3
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Quality Control Lead (Sterile Product Manufacturing) | Athlone, Ireland | Oct 23, 2026 | Oct 23, 2026 |
| Co-op, Integrated Insights & Analytics, Nephrology | Cambridge, MA | Oct 22, 2026 | Oct 7, 2026 |
| Director, Biotherapeutics Discovery | San Francisco, CA | Oct 22, 2026 | Oct 7, 2026 |
| Sr Scientist, Biomarker Bioanalytical Sciences | Cambridge, MA | Oct 22, 2026 | Oct 7, 2026 |
| Sr. Manager, Affiliate Finance - Fixed Term Contract | Toronto, Canada | Oct 22, 2026 | Oct 20, 2026 |
Trial and FDA signals
- New trial + clinical hiring Started a Phase 3 trial (NCT07444476, actual start Sep 8, 2026) (+2 other new trials); 19 clinical-operations roles open. ClinicalTrials.gov NCT07444476 (Sep 8, 2026)
Evidence (3 events)
- Sep 8, 2026 · ClinicalTrials.gov NCT07444476
leadSponsor.name='Biogen'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-08,type:ACTUAL}; studyFirstPostDate=2026-03-03; briefTitle="A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular At" - Jul 30, 2026 · ClinicalTrials.gov NCT07722546
leadSponsor.name='Biogen'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-30,type:ACTUAL}; studyFirstPostDate=2026-07-23; briefTitle="A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old" - Jul 21, 2026 · ClinicalTrials.gov NCT07662148
leadSponsor.name='Biogen'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-21,type:ACTUAL}; studyFirstPostDate=2026-06-23; briefTitle='A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18'
- Sep 8, 2026 · ClinicalTrials.gov NCT07444476
Timeline
- Trial start Phase 3: A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (R source ↗
- Trial start —: A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies source ↗
- Trial start Phase 1/Phase 2: A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS) source ↗
- Board tracked Radar started tracking this company’s job board (271 open jobs at last check). source ↗
- Trial start Phase 3: A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or source ↗
- Trial start Phase 3: A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec source ↗
- Trial start Phase 2: A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old source ↗
- Trial start Phase 1: A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebo source ↗
- Trial start Phase 3: A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA) source ↗
- Trial start Phase 3: A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammatio source ↗
- FDA FDA New indication / efficacy supplement: SPINRAZA (nusinersen sodium) — NDA209531/16, Mar 27, 2026. Applicant at approval: Biogen, Inc. source ↗
- Trial start Phase 2: A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation source ↗
- Trial start —: A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS) source ↗
- Trial start —: A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone source ↗
- Trial start Phase 1: A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants source ↗
- Trial start Phase 1: A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55 source ↗
- Trial start Phase 4: A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS) source ↗
- Trial start Phase 1: A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old source ↗
- Trial start —: A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy source ↗
- Trial start Phase 3: A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia source ↗
- Trial start Phase 3: A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) source ↗
- Trial start Phase 3: A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) source ↗
- Trial start Phase 1: A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled Diranersen (BIIB080) Co-administered With Diranersen in Healthy Adults source ↗
- Trial start Phase 1: A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK) source ↗
- Trial start Phase 1: A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways source ↗
Upcoming milestones
- Oct 20, 2026 (ESTIMATED) · Phase 2/Phase 3 · A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus · NCT05531565
- Oct 31, 2026 (ESTIMATED) · · A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administrat · NCT05925049
- Dec 1, 2026 (ESTIMATED) · Phase 3 · A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) · NCT06685757
- Feb 2, 2027 (ESTIMATED) · Phase 1 · A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants · NCT07225517
- Feb 5, 2027 (ESTIMATED) · · Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium) · NCT04317794
- Mar 29, 2027 (ESTIMATED) · · A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone · NCT07398469
- May 20, 2027 (ESTIMATED) · Phase 3 · A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis · NCT03958877
- May 26, 2027 (ESTIMATED) · Phase 4 · A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS) · NCT07223723
Open jobs 271
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Quality Control Lead (Sterile Product Manufacturing) | Athlone, Ireland | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Co-op, Integrated Insights & Analytics, Nephrology | Cambridge, MA | Oct 22, 2026 | Oct 7, 2026 | Entry |
| Director, Biotherapeutics Discovery | San Francisco, CA | Oct 22, 2026 | Oct 7, 2026 | Senior |
| Sr Scientist, Biomarker Bioanalytical Sciences | Cambridge, MA | Oct 22, 2026 | Oct 7, 2026 | Not stated |
| Sr. Manager, Affiliate Finance - Fixed Term Contract | Toronto, Canada | Oct 22, 2026 | Oct 20, 2026 | Not stated |
| Manager, Drug Safety - ICSR Processes | Cambridge, MA | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Regional Medical Lead, Rare Diseases SMA | Baar, Switzerland | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Partnership Lead, Rare Disease - Quebec | Quebec, Canada | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Sr. Manufacturing Technician – Manufacturing Maintenance | Research Triangle Park, NC | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Sr Manager, Global Regulatory Affairs, WCH | San Francisco, CA | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Associate Medical Director, Rare Disease - Friederichs Ataxia (US Medical Affairs) | Cambridge, MA | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Alternance – Assistant(e) Chef(fe) de Produit Maladies Rares (12 à 24 mois) | Paris, France | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Medical Affairs, Intern | Toronto, Canada | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Patient Advocacy Lead | Tokyo, Japan | Oct 20, 2026 | Oct 20, 2026 | Not stated |
| Corporate Communications Lead | Tokyo, Japan | Oct 20, 2026 | Oct 20, 2026 | Not stated |
| Senior PMS Lead | Tokyo, Japan | Oct 20, 2026 | Oct 20, 2026 | Not stated |
| Medical Director, US Medical Affairs – Rare Diseases (Friedreich's Ataxia) | Cambridge, MA | Oct 20, 2026 | Oct 20, 2026 | Not stated |
| Manager, Drug Safety - ICSR Processes | 2 locations (listed on the posting) | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Associate Director, Immunobiology Open Innovation | San Francisco, CA | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Engineer III, Manufacturing Sciences - Cell Culture | Research Triangle Park, NC | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Commercial Associate, Intern | Toronto, Canada | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| Senior Analyst, Record To Report (Spanish-speaking, Fixed Term 9-month) | Warsaw, Poland | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| Senior Manufacturing Engineer I | Athlone, Ireland | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| Sr. Associate III, Compliance - QRM Lead | Research Triangle Park, NC | Oct 16, 2026 | Oct 7, 2026 | Mid |
| EU CTR Submission Lead | Baar, Switzerland | Oct 16, 2026 | Oct 16, 2026 | Not stated |
| Senior Case Manager- Specialty | Research Triangle Park, NC | Oct 16, 2026 | Oct 18, 2026 | Not stated |
| Investigator I / II | Research Triangle Park, NC | Oct 16, 2026 | Oct 18, 2026 | Not stated |
| Senior Manager, Service Management – ServiceNow Platform | Cambridge, MA | Oct 16, 2026 | Oct 18, 2026 | Not stated |
| National Family Access Manager (FAM) | Field Locations | Oct 16, 2026 | Oct 18, 2026 | Not stated |
| Associate Director, Enterprise Architecture, Global Commercial & Medical IT | Research Triangle Park, NC | Oct 16, 2026 | Oct 18, 2026 | Not stated |
| Sr Manager, Medical Communications – Empaveli (US Medical Affairs) | Cambridge, MA | Oct 16, 2026 | Oct 18, 2026 | Not stated |
| Global Commercialization Director, Glomerulonephropathy (GN) | Baar, Switzerland | Oct 16, 2026 | Oct 18, 2026 | Not stated |
| Associate Director, Antisense Oligonucleotide Analytical Development | Cambridge, MA | Oct 16, 2026 | Oct 18, 2026 | Not stated |
| Head of Marketing, Rare Disease - Friedreich Ataxia | Cambridge, MA | Oct 15, 2026 | Oct 7, 2026 | Senior |
| Co-op, Healthcare Professional Marketing | Cambridge, MA | Oct 15, 2026 | Oct 14, 2026 | Entry |
| Senior Techno Functional Analyst – Supply Planning & External Collaboration | Baar, Switzerland | Oct 15, 2026 | Oct 15, 2026 | Senior |
| Analyste Financier - Alternant(e) | Paris, France | Oct 15, 2026 | Oct 15, 2026 | Mid |
| Associate Director, Launch Excellence, US Lupus | Cambridge, MA | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Co-op, Neuropsychiatry Strategy & Operations | Cambridge, MA | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Lead, Manufacturing - Large Scale Purification (Days) | Research Triangle Park, NC | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Sr Territory Business Manager - Specialty MS - Little Rock, AR | Little Rock, AR | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Director, US HCP Marketing - Lupus | Cambridge, MA | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Senior Associate II, Quality Audits | Research Triangle Park, NC | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Clinical Supply Lead Specialist- Bulk Logistics & Quality | 2 locations (listed on the posting) | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Associate Director, Enterprise Architecture, Global Commercial & Medical IT | Warsaw, Poland | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Senior Fill Finish Process Engineer | Athlone, Ireland | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Electrician II | Solothurn, Switzerland | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Sr. IT Solution Architect, Access Automation | 2 locations (listed on the posting) | Oct 14, 2026 | Oct 7, 2026 | Senior |
| (Senior) Medical Science Liaison - Ophthalmology (Southern CA, AZ, NM) | 2 locations (listed on the posting) | Oct 14, 2026 | Oct 7, 2026 | Mid |
| Associate Director, Program Management, Global Commercial Medical IT | Research Triangle Park, NC | Oct 14, 2026 | Oct 7, 2026 | Senior |
Clinical trials (lead sponsor) Showing 50 of 509
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07722546 | A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old | Phase 2 | Recruiting | Jul 30, 2026 | Jan 31, 2028 (estimated) |
| NCT07219043 | A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation | Phase 2 | Recruiting | Jan 5, 2026 | Feb 10, 2028 (estimated) |
| NCT05352919 | A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE) | Phase 3 | Enrolling by invitation | Jun 10, 2022 | May 3, 2032 (estimated) |
| NCT06953583 | A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia | Phase 3 | Active, not recruiting | Jun 9, 2025 | Nov 16, 2027 (estimated) |
| NCT07855211 | A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS) | Phase 1/Phase 2 | Not yet recruiting | Oct 22, 2026 | Jan 23, 2034 (estimated) |
| NCT07444476 | A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam | Phase 3 | Recruiting | Sep 8, 2026 | Jun 23, 2028 (estimated) |
| NCT05531565 | A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | Phase 2/Phase 3 | Active, not recruiting | Sep 13, 2022 | Oct 20, 2026 (estimated) |
| NCT07444489 | A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE) | Phase 3 | Enrolling by invitation | Apr 16, 2026 | Dec 31, 2031 (estimated) |
| NCT06935357 | A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | Phase 3 | Recruiting | May 8, 2025 | May 31, 2027 (estimated) |
| NCT06962800 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) | Phase 3 | Recruiting | May 22, 2025 | Jan 28, 2030 (estimated) |
| NCT03958877 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis | Phase 3 | Active, not recruiting | Oct 18, 2019 | May 20, 2027 (estimated) |
| NCT05042921 | Pediatric Spinal Muscular Atrophy (SMA) China Registry | Not listed | Active, not recruiting | Nov 18, 2021 | Sep 2, 2027 (estimated) |
| NCT07398469 | A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone | Not listed | Recruiting | Dec 22, 2025 | Mar 29, 2027 (estimated) |
| NCT07047820 | A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy | Not listed | Completed | Jun 30, 2025 | Aug 2, 2026 (actual) |
| NCT02255435 | A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia | Phase 2 | Completed | Jan 31, 2015 | Oct 31, 2019 (actual) |
| NCT06054893 | A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old | Phase 1 | Active, not recruiting | Jul 1, 2024 | Jun 4, 2030 (estimated) |
| NCT06555419 | A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK) | Phase 1 | Recruiting | Jan 16, 2025 | Sep 30, 2027 (estimated) |
| NCT07221669 | A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA) | Phase 3 | Recruiting | Apr 28, 2026 | Nov 28, 2028 (estimated) |
| NCT07223723 | A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS) | Phase 4 | Active, not recruiting | Dec 11, 2025 | May 26, 2027 (estimated) |
| NCT05658497 | Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) | Not listed | Recruiting | Oct 27, 2023 | Jul 6, 2032 (estimated) |
| NCT07444450 | A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec | Phase 3 | Recruiting | Sep 4, 2026 | Jul 27, 2029 (estimated) |
| NCT04729907 | A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD) | Phase 3 | Completed | Apr 19, 2021 | Jul 30, 2026 (actual) |
| NCT05618379 | Adult Spinal Muscular Atrophy (SMA) China Registry | Not listed | Active, not recruiting | Jan 6, 2023 | Jun 1, 2028 (estimated) |
| NCT06044337 | A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | Phase 3 | Enrolling by invitation | Oct 3, 2023 | Jun 26, 2029 (estimated) |
| NCT07662148 | A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebo | Phase 1 | Recruiting | Jul 21, 2026 | Jun 19, 2028 (estimated) |
| NCT04317794 | Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium) | Not listed | Active, not recruiting | Jul 2, 2019 | Feb 5, 2027 (estimated) |
| NCT06628687 | A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies | Not listed | Recruiting | Oct 26, 2026 | Apr 30, 2035 (estimated) |
| NCT06454721 | A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled Diranersen (BIIB080) Co-administered With Diranersen in Healthy Adults | Phase 1 | Completed | Jan 30, 2025 | Mar 5, 2026 (actual) |
| NCT05575011 | A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec | Phase 1 | Active, not recruiting | Oct 10, 2022 | Nov 14, 2031 (estimated) |
| NCT05399888 | A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age | Phase 2 | Active, not recruiting | Aug 24, 2022 | Mar 11, 2026 (actual) |
| NCT06685757 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) | Phase 3 | Active, not recruiting | Dec 3, 2024 | Dec 1, 2026 (estimated) |
| NCT05348785 | A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 | Phase 2 | Completed | Apr 19, 2022 | Mar 9, 2026 (actual) |
| NCT05688436 | A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies | Not listed | Active, not recruiting | Sep 24, 2021 | Jan 17, 2031 (estimated) |
| NCT06741657 | A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways | Phase 1 | Completed | Jan 2, 2025 | Mar 10, 2026 (actual) |
| NCT05067790 | A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND) | Phase 3 | Active, not recruiting | Jan 21, 2022 | Sep 24, 2027 (estimated) |
| NCT02283853 | Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) | 3 | Completed | Aug 28, 2014 | Jul 8, 2025 (actual) |
| NCT07297199 | A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55 | Phase 1 | Completed | Dec 12, 2025 | May 1, 2026 (actual) |
| NCT05925049 | A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS) | Not listed | Active, not recruiting | Jun 30, 2023 | Oct 31, 2026 (estimated) |
| NCT07133828 | A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old | Phase 1 | Recruiting | Aug 29, 2025 | Aug 6, 2026 (estimated) |
| NCT06623890 | A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors | Not listed | Recruiting | Dec 12, 2024 | Oct 1, 2029 (estimated) |
| NCT07259980 | A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS) | Not listed | Recruiting | Jan 2, 2026 | Dec 30, 2033 (estimated) |
| NCT04856982 | A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation | Phase 3 | Active, not recruiting | May 17, 2021 | Aug 7, 2027 (estimated) |
| NCT07483632 | A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) | Phase 3 | Not yet recruiting | Nov 16, 2026 | Jul 28, 2034 (estimated) |
| NCT05789758 | A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies | Not listed | Recruiting | Dec 15, 2023 | Oct 31, 2032 (estimated) |
| NCT05798520 | A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) | Phase 2 | Completed | Jul 25, 2023 | Feb 10, 2026 (actual) |
| NCT04895241 | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus | Phase 3 | Active, not recruiting | May 25, 2021 | Sep 30, 2026 (estimated) |
| NCT07225517 | A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants | Phase 1 | Recruiting | Dec 18, 2025 | Feb 2, 2027 (estimated) |
| NCT04961567 | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus | Phase 3 | Active, not recruiting | Jul 16, 2021 | Sep 27, 2026 (estimated) |
| NCT05265728 | A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis | Phase 3 | Terminated | Apr 26, 2022 | Jan 18, 2024 (actual) |
| NCT05083923 | A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS) | Phase 3 | Completed | Nov 18, 2021 | Sep 11, 2024 (actual) |
FDA records (last 2 years)
Connect
See your connections at Biogen on LinkedIn (search by name, results not checked)